Display options
Cite
Stanland LJ, Luftig MA. Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. Future Virol. 2018;13(11):803-818doi: 10.2217/fvl-2018-0071.
Stanland, L. J., & Luftig, M. A. (2018). Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. Future virology, 13(11), 803-818. https://doi.org/10.2217/fvl-2018-0071
Stanland, Lyla J, and Luftig, Micah A. "Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer." Future virology vol. 13,11 (2018): 803-818. doi: https://doi.org/10.2217/fvl-2018-0071
Stanland LJ, Luftig MA. Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer. Future Virol. 2018 Nov;13(11):803-818. doi: 10.2217/fvl-2018-0071. Epub 2018 Oct 24. PMID: 34367314; PMCID: PMC8345226.
Copy Download .nbib Format: NLM
Share it on

Future Virol. 2018 Nov;13(11):803-818. doi: 10.2217/fvl-2018-0071. Epub 2018 Oct 24.

Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer.

Future virology

Lyla J Stanland, Micah A Luftig

Affiliations

  1. Department of Molecular Genetics and Microbiology, Center for Virology, Duke University School of Medicine, Durham, NC, 27710, USA.

PMID: 34367314 PMCID: PMC8345226 DOI: 10.2217/fvl-2018-0071

Abstract

Epstein-Barr Virus (EBV) was the first discovered human tumor virus and is the etiological agent of B cell lymphomas and also epithelial cancers. Indeed, nearly 10% of gastric cancers worldwide are EBV-positive and display unique molecular, epigenetic, and clinicopathological features. EBV-positive gastric cancers display the highest rate of host genome methylation of all tumor types studied and harbor recurrent mutations activating PI3Kα, silencing ARID1A, and amplifying PD-L1. While EBV infection of B cells can be studied efficiently,

Keywords: EBV; Epstein-Barr virus; PI3K; gastric cancer; immunotherapy; methylation

References

  1. World J Gastroenterol. 2015 Nov 21;21(43):12261-73 - PubMed
  2. Clin Cancer Res. 2017 Jan 1;23(1):26-34 - PubMed
  3. Front Pharmacol. 2017 Aug 23;8:561 - PubMed
  4. Nat Genet. 2014 Jun;46(6):573-82 - PubMed
  5. J Virol. 2016 Apr 14;90(9):4383-93 - PubMed
  6. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9131-5 - PubMed
  7. J Natl Cancer Inst. 2014 Jun 04;106(7): - PubMed
  8. Virology. 2011 Apr 10;412(2):392-400 - PubMed
  9. Toxicol Pathol. 2006;34(5):599-608 - PubMed
  10. Mol Oncol. 2012 Apr;6(2):155-76 - PubMed
  11. Cancers (Basel). 2014 Nov 07;6(4):2259-74 - PubMed
  12. Cancer Res. 2009 Apr 1;69(7):2766-74 - PubMed
  13. Nat Microbiol. 2018 Feb;3(2):1-8 - PubMed
  14. J Virol. 2009 Aug;83(15):7749-60 - PubMed
  15. PLoS One. 2017 Aug 11;12(8):e0182852 - PubMed
  16. Chin J Cancer. 2014 Nov;33(11):549-55 - PubMed
  17. Sci Transl Med. 2016 Dec 14;8(369):369ra175 - PubMed
  18. J Gen Virol. 2005 Nov;86(Pt 11):3009-3019 - PubMed
  19. Oncogene. 2004 Nov 11;23(53):8619-28 - PubMed
  20. Clin Microbiol Rev. 2010 Oct;23(4):713-39 - PubMed
  21. Methods Mol Biol. 2017;1597:167-177 - PubMed
  22. J Virol. 2014 Oct;88(19):11442-58 - PubMed
  23. Int J Cancer. 2010 Oct 1;127(7):1570-83 - PubMed
  24. Mod Pathol. 1990 May;3(3):377-80 - PubMed
  25. Adv Virus Res. 2014;88:279-313 - PubMed
  26. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7257-65 - PubMed
  27. J Virol. 2018 Jan 2;92(2): - PubMed
  28. Oncotarget. 2017 Jul 4;8(27):44960-44975 - PubMed
  29. J Virol. 2015 May;89(10):5581-91 - PubMed
  30. Nature. 2013 Oct 24;502(7472):472-9 - PubMed
  31. Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 - PubMed
  32. Carcinogenesis. 2014 Apr;35(4):867-76 - PubMed
  33. Nat Genet. 2012 Dec;44(12):1321-5 - PubMed
  34. J Immunol. 2002 Nov 15;169(10):5673-8 - PubMed
  35. J Virol. 2003 Nov;77(22):12276-84 - PubMed
  36. World J Gastroenterol. 2014 Sep 14;20(34):12007-17 - PubMed
  37. Oncotarget. 2016 Dec 6;7(49):81512-81526 - PubMed
  38. Nat Genet. 2012 May;44(5):570-4 - PubMed
  39. Cancer Res. 2011 Dec 1;71(23):7187-97 - PubMed
  40. World J Gastroenterol. 2018 May 14;24(18):1942-1961 - PubMed
  41. Adv Exp Med Biol. 2018;1045:437-457 - PubMed
  42. Curr Treat Options Oncol. 2013 Jun;14(2):224-36 - PubMed
  43. Chin J Cancer. 2014 Dec;33(12):581-90 - PubMed
  44. Gastroenterology. 2015 Oct;149(5):1153-1162.e3 - PubMed
  45. Pathol Res Pract. 2011 Sep 15;207(9):529-37 - PubMed
  46. Nature. 2014 Sep 11;513(7517):202-9 - PubMed
  47. World J Gastroenterol. 2014 Apr 14;20(14):3916-26 - PubMed
  48. J Virol. 2015 Nov;89(22):11256-68 - PubMed
  49. Mol Pathol. 2000 Feb;53(1):37-42 - PubMed
  50. Virchows Arch. 2012 Oct;461(4):367-77 - PubMed
  51. Curr Protoc Mouse Biol. 2013 Dec 19;3(4):217-40 - PubMed
  52. Infect Agent Cancer. 2014 Nov 17;9(1):38 - PubMed
  53. Nature. 2014 Dec 18;516(7531):400-4 - PubMed
  54. PLoS Pathog. 2011 May;7(5):e1001338 - PubMed
  55. PLoS One. 2012;7(7):e40364 - PubMed
  56. J Pathol. 2012 Aug;227(4):392-403 - PubMed
  57. Br J Cancer. 2006 Feb 27;94(4):455-9 - PubMed
  58. Cancer Sci. 2009 Nov;100(11):2034-9 - PubMed
  59. J Virol. 1998 Oct;72(10):8321-6 - PubMed
  60. Gastrointest Cancer. 2017;7:1-11 - PubMed
  61. Cancer Biol Ther. 2014 Jun 1;15(6):655-64 - PubMed
  62. J Virol. 1998 May;72(5):4371-8 - PubMed
  63. Gut. 2016 Feb;65(2):202-13 - PubMed
  64. PLoS Pathog. 2015 Jan 15;11(1):e1004561 - PubMed
  65. Oncotarget. 2016 May 31;7(22):32925-32 - PubMed
  66. Oncotarget. 2017 Feb 7;8(6):10238-10254 - PubMed
  67. PLoS Pathog. 2015 Jun 12;11(6):e1004979 - PubMed
  68. Onco Targets Ther. 2016 Jan 07;9:203-10 - PubMed
  69. Mod Pathol. 2017 Mar;30(3):427-439 - PubMed
  70. Cancer Cell. 2014 Jul 14;26(1):136-49 - PubMed
  71. mBio. 2012 Jul 03;3(4):e00159-12 - PubMed
  72. Nat Microbiol. 2018 Feb;3(2):172-180 - PubMed
  73. J Gastric Cancer. 2016 Mar;16(1):1-7 - PubMed
  74. Update Cancer Ther. 2008 Mar;3(1):33-41 - PubMed
  75. Nat Rev Cancer. 2016 Dec;16(12):789-802 - PubMed
  76. Oxid Med Cell Longev. 2016;2016:6021934 - PubMed
  77. J Carcinog. 2014 Dec 19;13:14 - PubMed
  78. Mol Cancer Ther. 2014 May;13(5):1117-29 - PubMed
  79. Ann Med. 2014 Sep;46(6):372-83 - PubMed
  80. Elife. 2017 Apr 20;6: - PubMed
  81. Ann Oncol. 2017 May 1;28(5):1005-1014 - PubMed
  82. Curr Top Microbiol Immunol. 2017;400:149-168 - PubMed
  83. Exp Mol Med. 2015 Jan 23;47:e130 - PubMed
  84. Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):7-10 - PubMed
  85. Sci Rep. 2017 Mar 03;7:43627 - PubMed
  86. Oncotarget. 2017 Jul 21;8(33):55265-55279 - PubMed
  87. J Med Virol. 2007 Sep;79(9):1343-8 - PubMed
  88. Int J Cancer. 2013 May 1;132(9):2076-86 - PubMed
  89. J Pathol. 2017 Aug;242(4):391-399 - PubMed
  90. Viruses. 2012 Dec;4(12):3420-39 - PubMed
  91. Semin Cancer Biol. 2012 Apr;22(2):137-43 - PubMed
  92. Blood. 2016 Sep 8;128(10):1374-81 - PubMed
  93. Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3473-82 - PubMed
  94. Adv Exp Med Biol. 2013;754:3-29 - PubMed
  95. Cell Stem Cell. 2010 Jan 8;6(1):25-36 - PubMed
  96. Nat Mater. 2017 Nov;16(11):1155-1161 - PubMed

Publication Types

Grant support